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Dr Lansman. Let’s just start off the discussion with type A dis-
section. You get a call for an acute type A dissection at your insti-
tution. Where do they go? Are they admitted to the intensive care
unit (ICU), to the emergency room (ER), or to the operating room
(OR)?
Dr Szeto.As youmentioned earlier, our paradigm has been a di-
rect trip with a type A aortic dissection to the OR.
Dr Lansman. To the OR?
Dr Szeto. Correct. And with the changing paradigm of adjunct
endovascular techniques, we would send some selected patients to
the hybrid OR, depending on the clinical scenario.
Dr Lansman. As I mentioned in my talk, we adopted that strat-
egy early on, and I must say I think it has made the difference in at
least 10% of our patients, whom I don’t think would have made it
from the ER or the ICU or a standard workup to the OR. So our
protocol, just to amplify on that, is they are admitted to the OR.
The entire team is called in, the patient gets an echo on the table,
and if it is not a dissection, everyone goes home; but everybody is
there if it is an acute type A dissection.
Dr Esposito. They go to the OR with a transesophageal echo.
Dr Rahe-Meyer. We do the same.
Dr Roselli. Our patients are assessed in the ICU—we confirm
the diagnosis there—but we have an OR that is essentially always
mobilized. It is pretty quick.
DrHughes. It’s on a case-by-case basis. The majority of our pa-
tients are transferred in rather than coming in to our ER, but cer-
tainly if somebody presents to our ER with a dissection that is
a surgical candidate, we go straight to the OR. If it is an
85-year-old, we are going to want to see him first before we takeres: Authors have nothing to disclose with regard to commercial support.
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to the OR.
Dr Lansman. Let me just move on. Sowe have got them admit-
ted. Are there any patients you are not going to take to the operat-
ing room? You are just going to say, ‘‘I’m sorry. This is beyond our
limit.’’ Do you have any limits?
Dr Preventza. Actually, it is very rare we turn down patients
for surgery. Most of the time, if the patients come to us, we do
operate. There are cases—if somebody has had prior cardiac sur-
gery and comes to us with a type A dissection—when definitely
we wouldn’t rush to the OR. We would proceed a little more
semi-electively. If we have the 85-year-old with a neurologic in-
jury and a cerebrovascular accident, that is when, most of the
time, we discuss the situation with family and we see what their
wishes are. But the reality is that it’s very rare that we turn pa-
tients down.
Dr Lansman. Dr Di Eusanio, we know what your thoughts are
on coma, but what about age?
Dr Di Eusanio.Age, I think, is no contraindication to operating
for an acute type A dissection. There is no age limit. I think if the
patient is in good condition, presenting well with good hemody-
namics and no renal failure, I think that surgical therapy can be as-
sociated with better survival than medical therapy. So I don’t think
that we should give a number, like 90 years, 85 years, or 95 years. I
think it is a biologic matter.
Dr Lansman.We would certainly agree with that. Wilson, any
age indications or contraindications?
Dr Szeto. Nimesh Desai recently looked at our data looking at
exactly that—risk factors, and you alluded to that abstract earlier.
There are certainly markers of high-risk patients: patients who are
elderly, in their late 80s; patients with malperfusion; patients with
rupture, etc. We don’t, per se, absolutely say no, but it certainly
does sound a word of caution for us in terms of proceeding with
surgery. As Dr Preventza said, with redos oftentimes we proceed
in more of a delayed fashion. In a patient with previous coronary
bypass grafting, we would perhaps need more information about
the status of their coronary anatomy.We have also been very reluc-
tant to operate on patients with severe or devastating neurologic in-
jury. That’s the one group that—at least in our hands—we have
been very reluctant to offer emergency surgery.gery c March 2013
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sion. Eric, are you taking people straight to the OR with visceral
malperfusion?
Dr Roselli. Yes, we do. We would take them to the hybrid OR
right away and, not only mobilize our standard team, but we also
let the vascular surgeon on call know in case we need assistance
with possibly more complicated peripheral stenting afterward.
With regard to brain injury—comatose patients—we will get
a portable computed axial tomographic scan in the ICU and, if
we see that the brain looks okay, we take those patients to the OR
aswell. And looking at the data you showed, you saved a lot of those
comatose patients. So unless we have some sort of objective evi-
dence that their brain is gone, we try and save those folks, too.
Dr Lansman. So, getting back to the viscera, let’s say you get
a call from one of your referring hospitals. They have been watch-
ing someone for 2 days; they aren’t sure what is going on. Now
they realize that the patient has really had an acute abdomen for
a day. He is being transferred over; his pH is 7.1. What would
you do with that patient?
Dr Roselli. I think if that patient is still alive 2 days later and
talking to you, the bowel may be ischemic and not dead. So if
he is young, we will take him, and we will open his belly after
we open his chest, and take a look and shoot an angiogram and re-
vascularize things.
Dr Lansman. Are you still in the audience, Dr Deeb? Do you
want to comment about that? How would you handle that?
Dr G. Michael Deeb (Ann Arbor, Mich). If we think the patient
has end–organ damage, we will take him to the OR to a hybrid
suite. Our main goal is to revascularize that patient and then to sta-
bilize him and make sure he doesn’t have dead bowel before we
open his chest and try to prevent tamponade. If he has no evidence
of tamponade and he has evidence of dead bowel, he is going to die
of dead bowel. There are reasons for taking patients to the OR, and
we take them to the OR to try to prevent them from dying. And
there are different causes for patients dying. Not all patients die
from acute tamponade and rupture of their ascending aorta. And
so we try to list the complications in their order of severity, and
we try to attack the most severe first. So the particular patient
who has evidence of dead bowel, we would revascularize without
opening his chest, stabilize him, make sure his bowel is not dead—
or get rid of the dead bowel—prior to taking him to the OR if he
wasn’t tamponading.
Obviously, if we have a patient who comes in to our institution
that has both problems—tamponade and evidence of ischemia—
that is a patient that you have to treat right away for both problems.
We think that is an ideal patient for a frozen elephant trunk and
then treatment with the standard combined surgery as the group
at Penn and Cleveland Clinic do. But if a patient has evidence of
dead bowel, we wouldn’t proceed with opening the chest. We
would stabilize him. That’s just the way we do it. I’m not saying
it is right or wrong; it is just different.
Dr Preventza. We had a few patients like that, and the first
thing that we did was open the abdomen, especially if there was
a question about dead bowel. I think that if the bowel is dead or
if the patient is comatose, the mortality is very high, and it can al-
most be futile to try to do anything else. If the bowel is ischemic
but is not what we would call dead bowel, then we try to revascu-
larize after that.The Journal of Thoracic and CardDr Lansman.Visceral malperfusion. Any other opinions on the
panel?
Dr Szeto. As technology improves—and we are going to find
this out—there may be a small, selected group of patients whom
we should be treating with endografting for type A dissection.
Maybe these are patients to treat with an endovascular approach
for the ascending aorta. As you know, we have done a few patients
at Penn using endovascular techniques for correction of malperfu-
sion in the abdomen. In the near horizon, with technologic im-
provements, stenting type A aortic dissections in this small,
highly selected group of patients may be of some value.
Dr Lansman. I always wondered about that. It seems to me,
most of the tears are very close to the sinotubular junction, some-
times into the coronary ostia. How are you going to get a landing
zone that is going to exclude the tear?
Dr Szeto.Well, I think you have to be careful. The patients have
to be selected carefully. These are patients in dire condition. It is an
option if, to your best knowledge, you can tell based on a computed
tomographic (CT) scan where the tear site is. Oftentimes, as you
know, that is difficult, and you may have to do that in conjunction
with an intraoperative transesophageal echocardiography. These
are small numbers of selected patients. But there may be some
value in this technique for the future, if you know the tear is some-
where in the ascending aorta proper, and the patient is acidotic and
you just don’t think you can get him through an open operation.
This may be a method of delaying the insult—of getting the patient
through and then having options down the road.
Dr Roselli. Steve, when Michael Moon was a fellow at our in-
stitution, he did a retrospective analysis of a bunch of CT scans on
acute type A dissection patients with that question in mind, and
found that about two thirds of patients actually had about a centi-
meter between the tear and their coronaries, which would allow for
potential coverage of the entry tear.
Dr Lansman. I am not sure when you look right at it. Well, per-
haps a centimeter. Is that what you call a good landing zone these
days?
Dr Roselli. I have treated 2 such cases and it has worked, but it
has been in undoubtedly dire situations.
Dr Hughes. Well, with regard to malperfusion in the gut, the
only thing that I would add is you should obviously look at your
CT scans carefully and figure out the etiology of the malperfusion.
If it is static malperfusion—when the celiac and superior mesen-
teric artery are clearly dissected and thrombosed—even if you
fix the type A dissection, you are not going to restore flow in
that scenario, and that’s a very highly lethal problem. And that’s
the situation in which Dr Deeb and Patel’s complication-specific
approach is probably the best option, even though it’s not going
to be a great result. You might want to stent the descending aorta
and go after those branch vessels, and then, later, fix the type A if
you can get flow back to the gut. Because if you fix the type A dis-
section, it’s not going to help the visceral malperfusion.
Dr Lansman. I see Dr Bachet at the microphone. We shared
a panel with Dr Cooley about 20 years ago and the discussion
was about type A dissection. Somebody asked a question from
the audience: If they come in at 3 in the morning, can youwait until
8 in the morning to take them to the OR? I’m embarrassed to say I
thought you could. We no longer do that. Dr Bachet said we were
immoral. I didn’t realize I was dealing with a French philosopher.iovascular Surgery c Volume 145, Number 3S S223
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think that waiting for an acute dissection is immoral, indeed, de-
spite my old age. I have 2 questions and comments—1 for Dr Pre-
ventza and 1 for Dr Esposito. I will start with Dr Preventza.
I am quite surprised that one of the most important departments
of aortic surgery in the world has discovered cannulation of the in-
nominate artery in the 21st century. Wewere doing this for the past
30 years absolutely liberally, and I am stupid because I didn’t pub-
lish it. So I have 3 comments.
The first comment: The data you give about the complication,
morbidity, etc, have nothing to do with cannulation. You should
have exactly the same results whatever cannulation you use. Sec-
ond, I have 2 comments about the technique. Forget the Dacron
graft; it is completely useless. All innominate arteries are like
my thumb. You can put an aortic cannula in them directly. It is sim-
pler—two purse-string sutures and that is it. The last comment ap-
plies not only to your presentation, but to all the videos and slides
we have seen in these 2 days about arch surgery. I see people fight-
ing constantly with the innominate vein. Divide it, cut it; nothing
happens, and you have the whole space to do the arch surgery. That
is what I wanted to say about innominate artery cannulation. But it
is an old technique; it is not a new technique. For me, it was so nat-
ural to use it that I was really surprised to see it presented as an
innovation.
My second comment goes to Dr Esposito. A few months ago in
Bologna, at the aortic symposium of Dr Di Bartolomeo, I gave
a lecture comparing the evolution of aortic surgery with the evolu-
tion of the architecture and plastic arts in Italy between the renais-
sance and classicism to the baroque style, and your presentation
exactly illustrates that. We are entering a completely baroque,
not to say rococo, era.
What I mean is that I don’t really understand the rationale—and
I would like you to explain it to me—of your technique. Why is it
advantageous compared with conventional arch surgery with an el-
ephant trunk and, 2 months later, the same thing you do in your pa-
tients, a normal, completely conventional replacement of the
thoracoabdominal aorta? Because, first of all, when you say that
debranching is easy, I don’t know. Ten anastomoses that can bleed,
meters of Dacron that can thrombose, etc. And in the belly, it is
heavy surgery. It takes, I suppose, 2 or 3 hours to open the abdo-
men, to put in the graft, to sew all those Dacron grafts onto the re-
nal arteries, etc. Do you think that this is really easier and simpler
for the patient and for the surgeons than thoracoabdominal
surgery?
Dr Esposito. Thank you for your question, Jean. I was afraid
that you weren’t here to ask some questions of me. So I am really
happy to answer them.
Just saying it is easier means, of course, the whole evolution—
thinking of it in terms of what to do, whether classic therapy or
the new type of repair. In my experience of 6 years, what I say
is that for dissection or for a degenerative aneurysm, the treat-
ment of arch surgery in this way—with 2 simple anastomoses
and without the arch, without the frozen elephant trunk, and go-
ing to do a very anatomic correction of the bovine trunklike re-
placement of the carotid artery or innominate artery—looks
very good. This is my personal opinion. But I see that there are
a lot of people that share my idea, of course, with different
methods and so on.S224 The Journal of Thoracic and Cardiovascular SurSpeaking about the thoracoabdominal, of course I started vascu-
lar surgery with Prof Pierangeli many years ago, looking at him do-
ing operations. In everybody’s hands, and even for people with
a specialization in this type of surgery, it is a very hard operation.
And also the debranching in the open abdomen is a very long op-
eration. So we need to decrease it. But looking at the literature of
doing it from the iliac artery, I came to think that this type of ap-
proach is wrong because the iliac artery is not good. But from
the abdominal aorta, it is much easier to arrange debranching to
correct a very huge aorta subsequently. This is my opinion, of
course, and maybe there is somebody more experienced than I
am that can say what is wrong or what is right.
Dr Lansman. I know Eric has to leave a little early, but I have to
get my question in before he leaves. Perhaps you said it and I
missed it. Is there anyone in whom you are not going to do a fixed
elephant trunk on with an acute type A? Is it selective? How do you
choose?
Dr Roselli. Basically, it is for all the type 1 dissections that I
have run into. I initially thought I would be selective. The first cou-
ple of patients I saw had a tear in the arch; another patient had two
tears—1 in the descending aorta and 1 proximally—then the third
patient’s arch was>4 cm. After doing 3 or 4 of these in patients
who had what seemed like a good indication, I realized that it
was pretty easy, and so I have applied it to all the type 1 dissec-
tions. Certainly, I think we ought to study it, though.
Dr Lansman.My talk was on octogenarians. In an 82-year-old
woman with a type A, are you going to do a fixed elephant trunk?
Dr Roselli. I have an 87-year-old who was fishing on his boat,
and he’s doing fine, and I don’t have to deal with his upper de-
scending aorta now.
Dr Martin Czerny (Berne, Switzerland). I have a question for
Dr Trimarchi. I liked his idea, and when the first publication on this
issue came out, I applied this concept to our patient group. The
main problem for mewas to define which false lumen is really par-
tially thrombosed. So how do you differentiate between low flow
and real partial thrombosis, because I think there is a major differ-
ence. Actually, what came out in our analysis, which we published
recently, was that the thrombosis status of the false lumen was not
an independent predictor in our series; the only independent pre-
dictor with us was patency or closure of the primary entry tear.
So, in other words, I think it makes a substantial difference if
you have retrograde perfusion of the false lumen, which may, of
course, result in partial thrombosis because it is a blind sac, but
this flow is not highly pressurized. However, if flow is antegrade,
then it makes a huge difference, because then you have this blind
sac phenomenon.
So the first question would be: What is your exact definition of
partial false lumen thrombosis? I think that in the future, wewill be
able to identify the patients with functional imaging. So what we
do now: Do we subject each and every patient with an acute
type B dissection to cine magnetic resonance angiography? Do
we try to quantify the number of communications between lumina,
the volumes of both lumina, as well as a noninvasive measurement
of blood pressure in both lumina? I think somewhere there lies the
answer.
Dr Trimarchi. It is a very complicated, tough question. We
have had many thoughts about this. About how we define the pres-
ence of thrombus in the false lumen, we thought and thought, andgery c March 2013
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the venous phase of the CT scan. If we saw in the same section both
contrast and thrombus, we called this partial lumen thrombosis.
There are some papers—in particular, the second paper from the
Sueoshi group—who report saccular formation of the false lumen.
What I think is that we are in the presence of many variables that
we are trying to evaluate to understand which patients will have
such important aortic growth that they will develop an aneurysm.
I think that, up to now, we don’t have the complete answer to this.
We are probably evaluating several different conditions in the im-
aging of these patients.
We observed, for example, that the number of entry tears in an-
other paper is strictly associated with increasing aortic growth
rates. We ourselves have observed the most dramatic growth
when we have only 1 entry tear that has been detected, and the
best results in terms of reduced aortic growth rate when we have
4 entry tears. So we do not have saccular formation and low
flow. And another thing, as you published recently, is the inner ver-
sus the outer curvature. There are other variables that we are eval-
uating, such as spiral and straight on the same patients, the
presence of atherosclerosis, arch diameter, and the presence and
number of additional vessels that are intersected by the dissection.
So there is no one answer. But I think that in the next 2 or 3 years,
we will knowmuch more about those patients who are at increased
risk for aortic dilation.
DrDi Eusanio. I would just like to step back to typeA dissection
and frozenelephant trunks. InBologna,wehave done, thus far,more
than 120 cases, and only roughly 10% in patients with type A dis-
section. I believe that patient selection is crucial in these patients be-
cause the frozen elephant trunk increases significantly the duration
of extracorporeal circulation and circulatory arrest. So avery old pa-
tient would be likely to have a less satisfactory outcome.
I also think that there is a nice indication, an anatomic indica-
tion, for the frozen elephant trunk in type A dissection. That would
be a type A dissection with a very distal entry tear, let’s say in the
neighborhood of the origin of the left subclavian artery. These pa-
tients would otherwise require a complete arch replacement with
a very deep distal anastomosis, which may be very demanding
and potentially at risk for bleeding and rupture. So with a frozen
elephant trunk, the procedure may be greatly facilitated by per-
forming the distal anastomosis at the more proximal level—let’s
say proximal to the left subclavian artery—leaving the stent graft
to cover the distal entry tear and take care of the distal repair. So I
think that is a nice anatomic indication for the frozen elephant
trunk in type A dissection.
Dr Jason Sperling (Ridgewood, NJ). First, a comment on the
paper fromHouston regarding your technique of innominate artery
cannulation. I noticed you had about a 4% stroke in your series—
not a huge number—but I was wondering whether some of that
stroke incidence was from unnecessary instrumentation of the
left common carotid artery. We have a similar technique at our
place. We sew an 8-mm graft onto the innominate artery; my apol-
ogies to Dr Bachet. We only control the proximal innominate, and
we snare the left common carotid and cool to 28C. We keep the
radial blood pressure at 80mmHg, andmanipulate our flows based
on the forebrain oxygen saturations as seen on cerebral oximetry.
We have had 0 stroke in, now, about 50 or 60 arch cases. So I just
wonder if the instrumentation of the carotid artery is necessary,The Journal of Thoracic and Cardbecause I’ve never had to instrument the carotid artery to perfuse
it directly using this technique.
And my question was for the doctor from Hannover regarding
the fibrinogen injection. Like Factor VIII, we know Factor VII is
really good at stopping bleeding, but the cost is in strokes and
thrombotic events—thrombosed grafts. I was wondering if you
could comment whether any of those patients have had any throm-
botic complications.
Dr Preventza. First of all, to Dr Bachet, I agree with the fact
that Texas Heart is a major aortic surgery center, and I know that
Dr Coselli has used innominate artery cannulation before in the
past for quite a few years. But for the past few years, we have
used right axillary cannulation as a routine. Since June, there
have been 68 consecutive patients with innominate artery cannula-
tion. The reason that we did that is becausewe thought that perhaps
we could save some time and don’t always need to do an unneces-
sary incision. With regard to the innominate vein, we have never
really had a problem, so we haven’t really felt the need to divide it.
With regard to the comment about stroke, we had 3 patients
with stroke. One had extensive stroke and the 2 others actually
had partial recovery. When we did the analysis for neurologic
events, the P value for age and antegrade cerebral perfusion
(ACP) duration was significant. For 2 patients—including the 1
patient who had extensive stroke—the ACP time was prolonged.
The third women with a partial-deficit stroke was 86 years old.
So we didn’t really think that any of these 3 patients had a prob-
lem in which instrumentation contributed to the stroke. We
thought that the prolonged ACP time for the 2 patients as well
as the advanced age of the 1 elderly woman contributed to the
stroke. In most of these patients, we did a distal anastomosis
open or a complete arch, and they required coronary artery by-
pass, thoracic endovascular aortic repair (TEVAR), or a mitral
valve, as well; they were pretty complicated cases.
Dr Lansman. I am not sure I would like a thrombus hanging on
the side of my carotid indefinitely when you oversew that little
stump of graft. Is there any issue long term? Have you ever heard
of anything?
Dr Sperling. Because we do surveillance on all these patients
after their surgeries, you can actually see that stump on every sin-
gle computed axial tomographic scan, and it opacifies with con-
trast, at least for us. So I don’t think there is any necrosis. It is
an 8-mm graft that is quite big; there’s probably just some swirling
flow in there.
Dr Ian Nixon (Melbourne, Australia). The video demonstrates
a technique that we evolved 5 years ago of balloon rupture of the
dissection membrane. We do it on acute type A and acute type B
patients—on all-comers. It’s safe, reproducible, and simple, and
obliterates the false lumen entirely and totally eliminates malper-
fusion without further procedures. We think it is a remarkably
simple and safe thing to do. It looks radical and dramatic, but it
works surprisingly well.
Dr Lansman. And how far down does this go?
DrNixon. Throughout the dissection. Wewould go to the aortic
bifurcation, if needed. So we totally obliterate the false lumen
wherever it finishes.
Dr Lansman. Can you show the slide, please?
DrNixon.You can see that this technique has totally obliterated
the false lumen in the thoracic aorta and, in all but 1 patient, in theiovascular Surgery c Volume 145, Number 3S S225
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the aorta for a follow-up period of as long as 5 years. So having
insertion of a bare stent and disruption of the intimal flap does
not lead to further dilation of the aorta. It seems to heal exactly
the same after we have disrupted it for up to a follow-up of 5 years.
We do have access to branches that come off the false lumen by
wire, but there have been no instances when we have needed to
go back and stent or stent-graft those branches. They are already
perfused with disruption of the flap. The majority of patients in
whom we have done this have had a dissection complicated by
malperfusion. So the technique has been remarkably successful
and remarkably simple.
Dr Hughes. So why not do it in every type B dissection? Or do
you do that already?
Dr Nixon. We do.
Dr Hughes. Everyone?
Dr Nixon. We do, and in every type A, as well. Once we have
done the proximal surgical correction, on the table we do this exact
procedure for type A and for all type Bs.
Dr Hughes On the type A, how far proximally do you go then
with your repair? Just to the subclavian?
Dr Nixon. Yes, just to the subclavian.
Dr Hughes. You are not doing a full arch, so I guess you have
some residual short-segment dissections potentially in between
your ascending and—
Dr Nixon. Well, it depends whether you have a reentry in the
branch vessels or whether the tear goes through the arch. If the
reentry occurs in the branch vessels, then we would stent those
to block the reentry. It doesn’t entirely address the problem of
residual arch dissection, and we have some ideas on how to
do that, too.
DrHughes.Do you stent the arch vessels through the open arch
or do you it at the time when you put—
Dr Nixon.Wewould come back and do that at a second sitting.
Dr Hughes. When do you that part in the type As?
Dr Nixon. Before the patients go home. We reestablish flow in
every vessel, and we know that before they leave the OR. So we
have had no malperfusion, we have had no mesenteric ischemia,
we have had no renal failure. And it is a quick and reliable
1-step procedure that corrects the whole dissection anatomically,
and there is no risk of further complications from false lumen en-
largement of the distal aorta, whether it be thoracic or abdominal.
We produce an anatomically corrected aorta throughout.
Dr Trimarchi. I think it is the extension of the concept that
came out of the Study of Thoracic Aortic Type B Dissection Using
Endoluminal Repair (STABLE) trial with the Provisional Exten-
sion to Induce Complete Attachment (PETTICOAT) condition ap-
proach for Bs, but they applied this technique only for those type B
patients who had a complication. The results seem to be very good
in the short term and the mid term. It looks very good.
Dr Nixon. That is accurate. This is an evolution from the STA-
BLE trial that we designate as stabilized. So this is a further deriv-
ative from the STABLE group. The STABLE group ran up to about
5 years ago, and we have used this technique exclusively since then
in the acute patients with a normal-size aorta.
Dr Rahe-Meyer. I still have to answer the question of a col-
league about the safety issues—especially thromboembolic
events—while using fibrinogen concentrate. The simple answerS226 The Journal of Thoracic and Cardiovascular Surwould be there were no thromboembolic events in the fibrinogen
group, whereas there were 2 or 3 in the placebo group with more
allogeneic blood products. Taking into consideration that we
only had 61 patients treated, of course, it is really necessary to
have more sound safety data.
But I can tell you something more about my experience with
that product. In some parts of Europe, we have been using it for
more than 25 years now for perioperative bleeding, and it seems
really to be incredibly safe. The question is why. I think there is
a big difference between coagulation factors that influence the
thrombotic potential—prothrombotic or thrombin-building fac-
tors—which you find in NovoSeven or in prothrombin complex
concentrates, on the one hand, and passive substrates like fibrino-
gen concentrate or factor XIII concentrate, on the other hand,
which don’t influence the balance between thrombosis and antith-
rombosis. This may be the reason why I have not seen and I have
not heard of any real thromboembolic events that could be attrib-
uted to the administration of fibrinogen concentrate. In contrast, I
have heard of many complications of factor VII and PCC, and I
have seen some myself, and I am pretty cautious about administer-
ing these prothrombotic factor concentrates.
Dr Kuratani. During acute type B aortic dissection in Japan,
we almost never use expansion, even if it is a malperfusion patient.
Usually, entry tear closure after malperfusion injury is not good. I
have 1 question about the long-term results: Do you have some pa-
tients with a neointimal tear or some other problem on the distal
side?
Dr Nixon. They all have neointimal tears, because we disrupt
the whole of the dissection starting at the bottom end of the cov-
ered stent graft. So we are intentionally producing the intimal
tear. We haven’t had intimal tears from the proximal hook fixation
of the Cook TX2 grafts that we have used proximally; that hasn’t
been a problem.What we do is to rupture from the lower third or so
of the covered stent graft, which we take down to a segment of
aorta that is normal in total diameter and then start to disrupt the
dissection flap at that point.
It is true that the stabilized group that we did before had very
good results with no malperfusion, but that doesn’t totally address
the growth of the false aneurysm, and it doesn’t totally thrombose
the false aneurysm. We have 90% thrombosis in the thoracic aorta
using STABLE, but we still have about a 40% incidence of patent
false lumen in the abdominal aorta. And so this technique evolved
to address that.
And it also simplifies treatment, because doing it acutely with
a 1-step technique when the aorta is a normal size, we found that
we have no need to reintervene in anything. They don’t have a false
lumen; they don’t have malperfusion. They heal and they remain
stable. The aorta doesn’t grow. Sowe have a group of patients who
have, apart from their stent grafts, ostensibly normal CT scans of
their aorta. And this includes both type A and type B patients. So it
addresses the long-term evolution of the false aneurysm and late
complications of rupture, plus it addresses the malperfusion
issues.
Dr Michael Raabe (Winnipeg, Canada). I was just interested
in the panel’s management of a patient that we see not
infrequently—a patient with an acute type A dissection that goes
all the way down to the iliac arteries, and the CT scan shows
that the celiac artery comes off the true lumen, the superiorgery c March 2013
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the true lumen, and the other one off the false lumen. The CT ra-
diologist tells you, well, one of the kidneys is enhancing with con-
trast and the other one isn’t. So we do what most of the panel
earlier said, which is we deal with the original dissection and get
a live patient out of the OR. But I am interested in what do you
do with the visceral scenario that I just outlined, and what is the
timing of that intervention, especially given what we have heard
just recently about all the negative effects of a patent false lumen
in the long term?
Dr Szeto.Avery good question. As you know, our center, along
with Eric, has been one of the proponents of a frozen elephant
trunk at the time of the first operation. And what we learned early
on, painfully, is that patients, just as you have described, may not
benefit from that technique—patients with perfusion of the differ-
ent mesenteric arteries off different lumens.We have learned, from
our experience, that those are the patients we probably should
leave alone and not do a frozen elephant trunk and just do the stan-
dard proximal repair.
In terms of timing, every patient is different, obviously, but
again, we get them out of the OR, get them reperfused, resusci-
tated, and we watch them closely. If there is ever any sign of ab-
dominal deterioration, peritonitis, renal failure, that is when we
would have a very low threshold to go back to the OR either for
an open or an endovascular intervention, depending on the pathol-
ogy, malperfusion, rupture, etc.
Dr Lansman. One of the hot topics for the first 10 aortic sym-
posia was whether we should resect the tear for a type A dissection
and whether you should do an open distal anastomosis, and each
time it would be debated. Very quickly: Do you do an open distal
anastomosis and do you try and resect the tear?
Dr Preventza. Yes, we always do an open distal anastomosis
for a type 1 dissection.
Dr Di Eusanio. Yes, absolutely.
Dr Trimarchi. All cases, 100% of patients.
Dr Kuratani. No, we usually use a frozen elephant trunk.
Dr Hughes. We do an open distal anastomosis, but if the tear
was in the proximal descending thoracic aorta, I wouldn’t do a total
arch in an acute type A dissection; I would just leave it alone. It’s
not going to kill them in the short term.
Dr Lansman. I agree with that. You don’t know where the tear
is, however, if you don’t do the open anastomosis.
Dr Hughes. We do an open distal anastomosis 100% of the
time.
Dr Esposito. What we do is an open distal anastomosis, of
course, and then we eventually do debranching of the vessel if
we have to do a TEVAR.
Dr Szeto. An open distal anastomosis, yes.
Dr Lansman. Is there anybody not doing an open distal anasto-
mosis in the audience? Just 2 left; it used to be about a third. I guess
slow progress.
Dr Preventza, an uncomplicated type B dissection gets admit-
ted. How do you treat that patient in Texas?
Dr Preventza.Most of the time, if it is an uncomplicated type
B, first of all, we evaluate the CT scan based on Sundt’s paper. If
the false lumen is>22 mm, there is a high incidence of aneurysm
and death. Therefore, we tend—if the false lumen is>22 mm—to
stent. But we have to look carefully at the CT scan and really see ifThe Journal of Thoracic and Cardthis patient is going to benefit from early TEVAR. Other times, we
just do antihypertensive therapy.
Dr Di Eusanio. Uncomplicated type B: medical therapy.
Dr Lansman. And what are your indications for surgery?
Dr Di Eusanio. For surgery or for TEVAR?
Dr Lansman. Intervention.
Dr Di Eusanio. Complications, of course, are the indications
for intervention. So, refractory pain, malperfusion, increasing
size and evolution of the aortic lesion on the CT scan—the classic
criteria.
Dr Trimarchi.We initially treat with a medical approach, but,
of course, we pay much more attention to imaging now than before
to determine if we have some predictor that could indicate a need
for early treatment.
Dr Kuratani. I showed in my presentation that we have some
anatomic indication for the uncomplicated type B dissection in
our data:>40 mm of aortic diameter at the onset. And, for the un-
complicated case, we usually try the TEVAR operation.
Dr Hughes. An uncomplicated type B dissection would still be
managed medically. For the high-risk uncomplicated that I re-
ferred to—a patient with a 4-cm/22-mm false lumen—I don’t
know that you need to do him immediately. I think Thor’s data
say you have as long as 9 months to do those folks. I would be in-
terested to hear what the panel would say. If you are going to treat
those people, do you treat them in the acute phase or do you wait,
get a CT after a month, see how it looks, and treat them then? I
think we have tended to do that more. If it is really otherwise un-
complicated, we might just see what the 1-month CT looks like
and decide about TEVAR at that time, because I don’t think it
makes a difference to the result you get if you wait a month.
Dr Lansman. Is there a high-risk group that you are watching
carefully?
Dr Hughes. All the criteria you know—a 4-cm patent false lu-
men, a 22-mm false lumen, an intramural hematoma (IMH) patient
who develops a new penetrating ulcer in the proximal descending
thoracic aorta, refractory pain or hypertension—those you have to
treat. I think refractory hypertension is a little bit subjective; I’m
not sure how you define that.
Dr Lansman. I may have missed it in your talk, but a false lu-
men>4 cm and a patent false lumen—are you just bringing those
patients back and doing an intervention? Or are you watching
them?
Dr Hughes. If somebody came in and they had a 4-cm patent
false lumen and otherwise were completely uncomplicated, I
wouldn’t actually do them right away. I probably would see how
their 1-month CT scan looks, but I would tell them that there is
some chance they’re going to need—
Dr Lansman. You just watch them carefully?
Dr Hughes. Yes.
Dr Esposito. I underline the importance of the 22 mm for the
false lumen with false lumen thrombosis, which is very important
for us. So, in that case, what we do is debranching of the left sub-
clavian artery to the carotid, and then we put in an endoprosthesis.
Dr Szeto. A similar approach as mentioned by Drs Hughes and
Esposito, and some of the members of the panel. The majority of
time we treat uncomplicated type Bs medically, but there are some
anatomically high-risk patients, as you mentioned, that we treat
aggressively with TEVAR. Maybe not right away, as Chadiovascular Surgery c Volume 145, Number 3S S227
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number of patients have compliance issues. So if I know a guy is
not going to come back, I am more likely to treat him that same
admission.
Dr Lansman. A type A IMH comes in.
Dr Szeto. In general, unless there is a clinical scenario that
would preclude us from operating, we are fairly aggressive with
operating on type A IMHs. I know there are a lot of Japanese
data that suggest that there is a small set of patients that you might
be able to manage medically and watch, but at least in our series—
in a small handful of patients—the outcome has not been good,
meaning they rupture. So we have been fairly aggressive unless
there are medical reasons—prohibitive reasons—not to operate
on those patients.
Dr Lansman. All right. You may know that in Dr Safi’s group,
with a type A IMH, if the aorta is<5 cm in diameter and the he-
matoma is<1 cm thick, he operates on them, but he watches them
initially. They operate on them about day 7; they think that it is anS228 The Journal of Thoracic and Cardiovascular Sureasier operation. We are considering it, but Dr Spielvogel won’t let
me do it, so we haven’t done it yet.
Dr Esposito. It depends on the age and the comorbidities. If it is
a young patient, I really am aggressive. Otherwise, if it’s an 80-
year-old patient, we take control and we see what happens.
Dr Hughes. Pretty much the same. It seems these patients tend
to be more elderly in general; there are a lot of older patients. For
the 85-year-old with a lot of comorbidities, certainly with<a 5-cm
aorta and no pericardial effusion, we treat that patient medically.
But the young patient is going to get surgery.
Dr Lansman. Do we have an opinion from the Far East?
Dr Kuratani. Usually, we wait on the operation if it is an IMH.
But it depends on the thickness of this IMH diameter. Usually, we
check every month by CT scan. So careful follow-up of the patient
is very important.
Dr Lansman. It is really remarkable the difference in the liter-
ature from the East and from the West in the incidence and the
malignancy.gery c March 2013
